Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

October 10, 2006 updated by: Eisai Inc.

An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline, a Taxane, and Capecitabine

The purpose of this study is to determine if E7070 is an efficacious, safe, and tolerable treatment for patients with metastatic breast cancer who have failed, or could not tolerate, prior treatments with an anthracycline, a taxane, and capecitabine.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

250

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Edmonton, Alberta, Canada
  • United States
    • Alabama
      • Birmingham, Alabama, United States
      • Hoover, Alabama, United States
    • Arizona
      • Sedona, Arizona, United States
    • Colorado
      • Denver, Colorado, United States
    • Connecticut
      • Torrington, Connecticut, United States
    • Florida
      • Fort Myers, Florida, United States
      • Ocoee, Florida, United States
      • Tampa, Florida, United States
    • Illinois
      • Chicago, Illinois, United States
      • Skokie, Illinois, United States
      • Urbana, Illinois, United States
    • Indiana
      • Indianapolis, Indiana, United States
    • Kansas
      • Overland Park, Kansas, United States
    • Minnesota
      • Minneapolis, Minnesota, United States
    • Missouri
      • St. Louis, Missouri, United States
    • New York
      • Albany, New York, United States
    • North Carolina
      • Winston-Salem, North Carolina, United States
    • Ohio
      • Kettering, Ohio, United States
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
      • Tulsa, Oklahoma, United States
    • Pennsylvania
      • Clairton, Pennsylvania, United States
      • Pittsburgh, Pennsylvania, United States
      • Wexford, Pennsylvania, United States
    • South Carolina
      • Greenville, South Carolina, United States
    • Texas
      • Austin, Texas, United States
      • Dallas, Texas, United States
      • Fort Worth, Texas, United States
      • Fredericksburg, Texas, United States
      • Houston, Texas, United States
      • Irving, Texas, United States
      • Tyler, Texas, United States
    • Virginia
      • Fairfax, Virginia, United States
    • Washington
      • Spokane, Washington, United States
      • Vancouver, Washington, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Patients must be female,
  • Patients must have histologically or cytologically confirmed metastatic breast cancer,
  • Patients must either have tumors that are resistant/refractory to chemotherapy with an anthracycline, a taxane, capecitabine, and appropriate Herceptin therapy, or tumors that cannot be treated with these agents due to patient's treatment toxicity; therefore, patients must have received 2 prior chemotherapies but no more than 3 prior chemotherapies in the metastatic setting,
  • Patients must have at least one uni-dimensionally measurable lesion according to the RECIST criteria in at least one site that has not been irradiated,
  • Patients must be aged >= 18 years,
  • Patients must have a Karnofsky Performance Status of >= 70%,
  • Patients must have a life expectancy of >= 3 months,
  • Patients must have adequate renal function as evidenced by serum creatinine <= 1.5 mg/dL, or if > 1.5 but <= 1.8 mg/dL, then a creatinine clearance of >= 45 mL/min,
  • Patients must have adequate bone marrow function as evidenced by absolute neutrophil count of >= 1.5 x 109/L, hemoglobin >= 9.0 g/dL, and platelet count >= 100 x 109/L,
  • Patients must have adequate liver function as evidenced by bilirubin of <= 1.5 times the upper limits of normal (ULN); alkaline phosphatase <= 3 times ULN and alanine transaminase (ALT) and aspartate transaminase (AST) <= 3 times ULN, unless related to liver metastasis, in which case <= 5 x ULN,
  • Patients must have serum electrolytes including calcium (corrected for albumin), magnesium, and potassium (corrected) within normal limits,
  • Patients must be willing and able to complete the FACT-B questionnaire,
  • Patients must be willing and able to comply with the study protocol for the duration of the study, and
  • Patients must give written informed consent prior to any study specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria:

  • Patients must not have metastatic disease that can be completely surgically resected,
  • Patients who received adjuvant taxane must not have experienced disease progression within 12 months of beginning that therapy,
  • Patients must not have received chemotherapy, hormonal therapy, or Herceptin within 2 weeks of E7070 treatment start and must have recovered from any chemotherapy-related or other therapy-related toxicity at study entry,
  • Patients must not have received investigational drugs including immunotherapy, gene therapy, or other biologic therapy; antineoplastic therapy; or radiation therapy (other than required for palliation of bone pain or chest ulceration) within 2 weeks of E7070 treatment,
  • Patients must not have received prior treatment with Mitomycin C or nitrosoureas,
  • Patients must not have undergone high dose chemotherapy with hematopoietic stem cell rescue,
  • Patients must not have untreated brain metastases (Patients who have been treated for central nervous system (CNS) metastases must be asymptomatic and radiologically stable [not receiving radiation] and must not have been receiving steroids for 4 weeks prior to entry.

Patients without known CNS metastases who are symptomatic for CNS metastasis must be evaluated with a CT scan or MRI scan prior to E7070 treatment.),

  • Patients must not have had major surgery without full recovery within 4 weeks of E7070 treatment start,
  • Patients must not have pulmonary lymphatic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen,
  • Patients must not have leptomeningeal metastasis,
  • Patients must not have evidence of clinically relevant ascites or pleural effusion requiring more than one isolated paracentesis or pleurocentesis per month prior to study start,
  • Patients must not be expected to require more than one isolated paracentesis or pleurocentesis per month during the study for the treatment of clinically relevant ascites or pleural effusion,
  • Patients must not be pregnant or breast-feeding and must practice adequate contraception if not surgically sterile,
  • Patients must not have severe medically uncontrolled intercurrent illness/infection,
  • Patients must not have had unstable angina or myocardial infarction in the past 6 months,
  • Patients must not have serious cardiac arrhythmia or symptomatic congestive heart failure >= Grade II (NYHA classification),
  • Patients must not have a history of prolonged QT, QTc > 470 ms (Bazett's correction) at entry, or history of torsade de pointes,
  • Patients must not have recent history (<= 12 months) of active or chronic viral hepatitis,
  • Patients must not have organ allografts,
  • Patients must not have known history of HIV positivity,
  • Patients must not have a history of hypersensitivity to sulfonamides,
  • Patients must not have a history of uncontrolled seizures,
  • Patients must not have had a prior malignancy, other than carcinoma in situ of the cervix or nonmelanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence, or
  • Patients must not have other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Objective Response Rate

Secondary Outcome Measures

Outcome Measure
Safety
Quality of Life
Tolerability
Overall Survival
Duration of Response
Time-to-Progression

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eisai Inc.

Investigators

  • Study Director: Sandra Silberman, M.D., Eisai Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2004

Study Completion

May 1, 2005

Study Registration Dates

First Submitted

March 24, 2004

First Submitted That Met QC Criteria

March 24, 2004

First Posted (Estimate)

March 25, 2004

Study Record Updates

Last Update Posted (Estimate)

October 11, 2006

Last Update Submitted That Met QC Criteria

October 10, 2006

Last Verified

October 1, 2006

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E7070-A001-211

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Neoplasms

Clinical Trials on E7070

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe